MSS/ MMRp

我们是谁

  • 4 月 5, 2022
    Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors
  • 4 月 5, 2022
    A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
  • 4 月 5, 2022
    测试不同剂量的 BI 1823911 单独或与其他药物联合用于不同类型的 KRAS 基因突变晚期癌症患者的研究
  • 4 月 5, 2022
    CR6086 联合 Balstilimab 治疗 pMMR-MSS 转移性结直肠癌患者的 Ib/IIa 期研究
  • 4 月 5, 2022
    用于治疗结直肠腹膜转移瘤的 PIPAC
  • 4 月 5, 2022
    Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
  • 4 月 5, 2022
    A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
  • 4 月 5, 2022
    Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
  • 4 月 5, 2022
    A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
  • 4 月 5, 2022
    A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer